HUWE1: A Promising Drug Target / Biomarker (G10075)

Target Name: HUWE1

NCBI ID: G10075

HUWE1

HUWE1: A Promising Drug Target / Biomarker

HUWE1 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of cell growth and differentiation, and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Despite its widespread expression, much is still not known about HUWE1. Its function and regulation are still the subject of ongoing research, and there is a need for further studies to fully understand its implications.

One potential way to study HUWE1 is as a drug target or biomarker. In this context, HUWE1 can be used as a target for small molecules or antibodies that can modulate its activity and behavior. This approach has the potential to identify new treatments for a variety of diseases.

HUWE1 as a Drug Target

HUWE1 has been shown to play a role in a number of cellular processes that are important for cancer growth and progression. For example, studies have shown that HUWE1 can promote the growth and survival of cancer cells, and that it is involved in the development of a type of cancer called melanoma.

In addition, HUWE1 has also been shown to contribute to the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. These conditions are characterized by the progressive loss of brain cells, and are some of the most common causes of dementia and other cognitive impairments.

HUWE1 has also been implicated in autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. These conditions involve an overactive immune system that causes inflammation and damage to body tissues.

HUWE1 as a Biomarker

In addition to its role as a drug target, HUWE1 has also been shown to be a potential biomarker for a number of diseases. For example, studies have shown that HUWE1 levels are elevated in the brains of individuals with Alzheimer's disease, and that they are associated with the development of the condition.

Similarly, HUWE1 has been shown to be elevated in the blood of individuals with Parkinson's disease, and that it is associated with the development of the condition.

Another study found that HUWE1 levels were elevated in the urine of individuals with rheumatoid arthritis, and that these levels were associated with the severity of the condition.

In addition to its potential as a biomarker, HUWE1 may also be used as a diagnostic tool for certain diseases. For example, studies have shown that HUWE1 is expressed in the brains of individuals with neurofibrillary tangles, which are a hallmark of Alzheimer's disease. Similarly, HUWE1 has been shown to be expressed in the blood of individuals with Parkinson's disease.

Conclusion

HUWE1 is a protein that is involved in a number of cellular processes that are important for health and disease. While much is still not known about its function and regulation, its potential as a drug target or biomarker is an exciting area of research. Further studies are needed to fully understand its implications and to develop new treatments for a variety of diseases.

Protein Name: HECT, UBA And WWE Domain Containing E3 Ubiquitin Protein Ligase 1

Functions: E3 ubiquitin-protein ligase which mediates ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:15989957, PubMed:19713937, PubMed:15567145, PubMed:15767685, PubMed:18488021, PubMed:17567951, PubMed:19037095, PubMed:20534529, PubMed:30217973). Regulates apoptosis by catalyzing the polyubiquitination and degradation of MCL1 (PubMed:15989957). Mediates monoubiquitination of DNA polymerase beta (POLB) at 'Lys-41', 'Lys-61' and 'Lys-81', thereby playing a role in base-excision repair (PubMed:19713937). Also ubiquitinates the p53/TP53 tumor suppressor and core histones including H1, H2A, H2B, H3 and H4 (PubMed:15567145, PubMed:15767685, PubMed:15989956). Ubiquitinates MFN2 to negatively regulate mitochondrial fusion in response to decreased stearoylation of TFRC (PubMed:26214738). Ubiquitination of MFN2 also takes place following induction of mitophagy; AMBRA1 acts as a cofactor for HUWE1-mediated ubiquitination (PubMed:30217973). Regulates neural differentiation and proliferation by catalyzing the polyubiquitination and degradation of MYCN (PubMed:18488021). May regulate abundance of CDC6 after DNA damage by polyubiquitinating and targeting CDC6 to degradation (PubMed:17567951). Mediates polyubiquitination of isoform 2 of PA2G4 (PubMed:19037095). Acts in concert with MYCBP2 to regulate the circadian clock gene expression by promoting the lithium-induced ubiquination and degradation of NR1D1 (PubMed:20534529). Binds to an upstream initiator-like sequence in the preprodynorphin gene (By similarity). Mediates HAPSTR1 degradation, but is also a required cofactor in the pathway by which HAPSTR1 governs stress signaling (PubMed:35776542)

The "HUWE1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HUWE1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets